Stock Financial Ratios, Dividends, Split History

DKL / Delek Logistics Partners LP financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price27.10
Volume29,100.00
Market Cap ($M)14.11
Enterprise Value ($M)9.43
Book Value ($M)-130.65
Book Value / Share-262.55
Price / Book-0.48
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding2 24,382,633
Common Shares Outstanding 497,604
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-2.37
Return on Assets (ROA)0.17
Return on Equity (ROE)-5.23
Balance Sheet (mrq) ($M)
Assets665.95
Liabilities796.59
Quick Ratio0.93
Current Ratio1.61
Income Statement (mra) ($M)
Sales Revenue Net538,075,000.00
Sales Revenue Services Net381,795,000.00
Sales Revenue Goods Net0.00
Revenue From Related Parties156,280,000.00
Equity Method Investment Summarized Financial Information Revenue28,805,000.00
Operating Income88.18
Net Income69.41
Cash Flow Statement (mra) ($M)
Cash From Operations87.70
Cash from Investing-30.67
Cash from Financing-30.67
Identifiers and Descriptors
CUSIP24664T103
Central Index Key (CIK)1552797
Related CUSIPS
24664T903 24664T953

Split History

Stock splits are used by Delek Logistics Partners LP to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

A Discounted Backdoor Into An 18% Yield - Buyout Should Close Very Soon

2h seekingalpha
The deal is supposed to close by the end of June - all board, unitholder and state approvals have been met. (9-0)

50 Energy Sector Top Yield Dividend Stocks For June

2018-06-17 seekingalpha
Energy firms with over 5% dividend yield showed a refining & marketing firm tops on its list, CrossAmerica Partners, for upside and net gains, and Sanchez Midstream for yield. (10-0)

90 Champions, Contenders And Challengers Are Wall Street Dividend Stars For June

2018-06-12 seekingalpha
Champion dividend stocks sustain 25 or more annual dividend increases; Contenders show 10 to 24; Challengers have 5 to 9. WallStar selections all show .7% or higher price target upsides. (35-0)

Delek Logistics Partners (DKL) Presents At MLP & Energy Infrastructure Conference - Slideshow

2018-05-23 seekingalpha
The following slide deck was published by Delek Logistics Partners LP in conjunction with this event. (2-0)

30 Top Dividend Challenger Gains Led By EQT Midstream Partners, Hoegh LNG Partners, And Westlake Chemical Per Broker Targets For May

2018-05-09 seekingalpha
30 Top Dividend Challenger stocks ranged in yield from 7.13% to 12.32%. The top 10 were PBVX, SIR, DDR, HMLP, ABR, DKL, NRZ, SRLP, GME, and SUN. (49-1)

CUSIP: 24664T103